Retinoic acid-inducible gene I (RIG-I) agonist therapy activates proinflammatory transcription factors STAT1 and NF-κB and triggers external apoptotic pathways and pyroptosis, a highly immunogenic form of cell death in breast cancer cells [69]. Here, RIGI is linked to breast carcinoma.